Grifols SA, a pharmaceutical company based in Spain, is currently in talks with banks to refinance a debt of around €1.4 billion ($1.48 billion). This debt includes bonds that will mature next year as well as a revolving credit line.

CEO Nacho Abia recently confirmed in an interview that the company's main focus is on refinancing €370 million in bonds that are due in 2025. Abia emphasized the importance of maintaining financial flexibility rather than relying solely on cash flow for repayment.

In addition to this, Grifols is also seeking to extend a $1 billion revolving credit facility that is set to expire in November 2025. These negotiations are crucial for the company's financial stability as there are growing concerns among investors regarding its ability to meet upcoming financial obligations.